Prevention of stroke. [1/7] Antiplatelet therapy. In: Canadian best practice recommendations for stroke care.

GUIDELINE TITLE [1/7]
Prevention of stroke. Antiplatelet therapy. In: Canadian best practice recommendations for stroke care.

BIBLIOGRAPHIC SOURCE(S)
Lindsay P, Bayley M, Hellings C, Hill M, Woodbury E, Phillips S. Prevention of stroke. Antiplatelet therapy. In: Canadian best practice recommendations for stroke care. CMAJ 2008 Dec 2;179(12 Suppl):E26-9.

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: Stroke prevention. Antiplatelet therapy. In: Canadian best practice recommendations for stroke care: 2006. Ottawa (ON): Canadian Stroke Network, Heart & Stroke Foundation of Canada; 2004. p. 32-5.

The Canadian Best Practice Recommendations for Stroke Care include an ongoing plan to formally update the recommendations every 2 years to ensure that the best practice recommendations remain current and are coordinated with other similar initiatives nationally and internationally.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

November 17, 2009 - Plavix (clopidogrel): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of new safety information concerning an interaction between clopidogrel (Plavix) and omeprazole (Prilosec/Prilosec OTC) used to reduce stomach acid. New data show that when clopidogrel and omeprazole are taken together, the effectiveness of clopidogrel is reduced.

abrir aquí para acceder al documento NGC AHRQ completo:
Prevention of stroke. Antiplatelet therapy. In: Canadian best practice recommendations for stroke care.